Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Breast test 'could prevent needless chemo'

  • Comment

Thousands of breast cancer sufferers could be spared unnecessary chemotherapy as a result of a new test, its makers have claimed.

The Oncotype DX test analyses a genetic sample taken from a patient’s tumour and determines whether chemotherapy would be useful in the treatment of the patient or not.

The test, which only works for those who have been newly diagnosed oestrogen-positive, node negative breast cancer, could benefit many of the 45,000 women who get the disease every year, molecular diagnostic company Genomic Health said.

People cannot currently get the test, which has been validated in 13 studies of 4,000 patients, on the NHS and have to pay about £2,500 if they want to take it.

A spokesman for the company said: “At the moment, doctors use measures such as tumour size and grade to determine whether to treat women with chemotherapy after surgery, typically deciding to use it in around half of cases.

“However, studies show that when doctors use the Oncotype DX test, they change their minds on use of chemotherapy in up to 34% of cases.

“In approximately 24% of cases, doctors decide not to prescribe chemotherapy after all, saving women from unpleasant side-effects of chemotherapy.”

“In 10% of cases, doctors using the test realise that chemotherapy is actually needed when previously they thought hormone therapy alone would be sufficient.”


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.